To the Editor,
The COVID-19 vaccines approved so far for use in the European Union (EU) include those from Pfizer/BioNTech®, Moderna® and AstraZeneca®. Two severe cases of anaphylaxis that were resolved after treatment were reported on the second day of the vaccination program. In the following days, an additional potential allergic reaction to the Pfizer/BioNTech® vaccine was described in the United Kingdom (UK) and another eight cases were reported in the United States (US). This triggered the need to provide recommendations on how to manage the safety concerns that had been raised.

Clique aqui para aceder à Carta ao Editor (apenas em inglês).